Trials / Completed
CompletedNCT05813561
The Efficacy and Safety of DWP14012 in Chinese Patients With Reflux Esophagitis
A Multicenter, Randomized, Double-Blind, Active-Parallel-Controlled, Phase 3 Clinical Study to Investigate the Efficacy and Safety of DWP14012 in the Treatment of Reflux Esophagitis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 332 (actual)
- Sponsor
- Daewoong Pharmaceutical Co. LTD. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy, safety, and cost-effectiveness of DWP14012 40 mg compared to esomeprazole magnesium enteric-coated tablets for the treatment of reflux esophagitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DWP14012 | DWP14012 40mg |
Timeline
- Start date
- 2021-12-30
- Primary completion
- 2022-07-23
- Completion
- 2023-02-17
- First posted
- 2023-04-14
- Last updated
- 2023-04-14
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05813561. Inclusion in this directory is not an endorsement.